FGFR1_HUMAN,M1T,0.949,Altered Disordered interface (Pr = 0.20 | P = 0.04); Altered Signal peptide (Pr = 0.12 | P = 1.6e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000355,-
FGFR1_HUMAN,W2K,0.890,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.19 | P = 7.3e-04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000351|ELME000355,-
FGFR1_HUMAN,S3G,0.459,-,-,-
FGFR1_HUMAN,W4F,0.859,Altered Disordered interface (Pr = 0.23 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000137|PS00005,-
FGFR1_HUMAN,L7R,0.930,Altered Disordered interface (Pr = 0.76 | P = 1.5e-05); Altered Signal peptide (Pr = 0.13 | P = 1.3e-03), ELME000106|ELME000137|ELME000146|ELME000233,-
FGFR1_HUMAN,F9L,0.731,Altered Signal peptide (Pr = 0.17 | P = 1.1e-03); Altered Disordered interface (Pr = 0.17 | P = 0.04), ELME000041|ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,F9V,0.758,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.16 | P = 1.2e-03), ELME000041|ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,A11G,0.714,Altered Signal peptide (Pr = 0.15 | P = 1.6e-03), ELME000041|PS00008,-
FGFR1_HUMAN,A11N,0.822,Altered Signal peptide (Pr = 0.15 | P = 1.6e-03); Gain of GPI-anchor amidation at A11 (Pr = 0.02 | P = 0.01), ELME000041,-
FGFR1_HUMAN,L13G,0.941,Altered Signal peptide (Pr = 0.16 | P = 4.9e-04), ELME000041|ELME000052|ELME000333|PS00008,-
FGFR1_HUMAN,V14G,0.896,Altered Signal peptide (Pr = 0.18 | P = 4.1e-04); Altered Stability (Pr = 0.09 | P = 0.05), ELME000041|ELME000052|ELME000333,-
FGFR1_HUMAN,V14R,0.919,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.20 | P = 2.9e-04), ELME000041|ELME000052|ELME000146|ELME000333,-
FGFR1_HUMAN,V14Y,0.925,Altered Signal peptide (Pr = 0.19 | P = 3.3e-04), ELME000041|ELME000052|ELME000080|ELME000182|ELME000333,-
FGFR1_HUMAN,T17A,0.641,Altered Signal peptide (Pr = 0.22 | P = 5.7e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05), ELME000052|ELME000053,-
FGFR1_HUMAN,L18E,0.902,Altered Signal peptide (Pr = 0.21 | P = 2.7e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03), ELME000052|ELME000053|ELME000064|ELME000147|ELME000220|PS00006,-
FGFR1_HUMAN,L18P,0.941,Altered Signal peptide (Pr = 0.21 | P = 2.6e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03), ELME000052|ELME000053|ELME000136|ELME000159,-
FGFR1_HUMAN,R22H,0.433,-,-,-
FGFR1_HUMAN,R22K,0.412,-,-,-
FGFR1_HUMAN,P23I,0.721,Altered Signal peptide (Pr = 0.37 | P = 2.4e-05); Loss of Intrinsic disorder (Pr = 0.35 | P = 0.04); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000064|ELME000136|ELME000155|ELME000159,-
FGFR1_HUMAN,P25R,0.663,Gain of ADP-ribosylation at P25 (Pr = 0.31 | P = 3.1e-03); Loss of Loop (Pr = 0.27 | P = 0.03); Altered Signal peptide (Pr = 0.21 | P = 2.4e-04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q30 (Pr = 0.07 | P = 0.02), ELME000005|ELME000051|ELME000062|ELME000064|ELME000106|ELME000136|ELME000155|ELME000159|ELME000220|ELME000239,-
FGFR1_HUMAN,L27T,0.827,Gain of Intrinsic disorder (Pr = 0.40 | P = 8.8e-03); Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.08 | P = 0.01); Altered Signal peptide (Pr = 0.04 | P = 2.5e-03), ELME000005|ELME000063|ELME000064|ELME000155|ELME000159|ELME000220|ELME000358|PS00006,-
FGFR1_HUMAN,P28S,0.533,Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.07 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 5.1e-03), ELME000005|ELME000064|ELME000155|ELME000220|PS00006,-
FGFR1_HUMAN,Q32K,0.285,-,-,-
FGFR1_HUMAN,G35K,0.376,-,-,-
FGFR1_HUMAN,V38E,0.456,-,-,-
FGFR1_HUMAN,S42A,0.215,-,-,-
FGFR1_HUMAN,R58Q,0.506,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Gain of Disulfide linkage at C55 (Pr = 0.22 | P = 0.01), None,-
FGFR1_HUMAN,N65D,0.292,-,-,-
FGFR1_HUMAN,Q72K,0.284,-,-,-
FGFR1_HUMAN,D90E,0.223,-,-,-
FGFR1_HUMAN,V92N,0.335,-,-,-
FGFR1_HUMAN,V92T,0.213,-,-,-
FGFR1_HUMAN,A94G,0.186,-,-,-
FGFR1_HUMAN,A100T,0.397,-,-,-
FGFR1_HUMAN,T141S,0.096,-,-,-
FGFR1_HUMAN,N143S,0.291,-,-,-
FGFR1_HUMAN,L245F,0.878,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.19 | P = 0.01); Loss of N-linked glycosylation at N240 (Pr = 0.13 | P = 8.1e-03); Gain of Sulfation at Y243 (Pr = 0.02 | P = 0.03), ELME000052|ELME000333,-
FGFR1_HUMAN,T318S,0.466,-,-,-
FGFR1_HUMAN,L328A,0.892,Altered Stability (Pr = 0.57 | P = 1.2e-03); Altered Transmembrane protein (Pr = 0.29 | P = 4.0e-04); Gain of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01), ELME000122|ELME000137|ELME000334|ELME000335,-
FGFR1_HUMAN,R329Q,0.472,-,-,-
FGFR1_HUMAN,F333E,0.891,Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Gain of B-factor (Pr = 0.27 | P = 0.01); Altered Metal binding (Pr = 0.17 | P = 0.05); Loss of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000334|PS00001|PS00006,-
FGFR1_HUMAN,D335Q,0.922,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Loss of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01); Gain of Pyrrolidone carboxylic acid at D335 (Pr = 0.05 | P = 0.04), PS00006,-
FGFR1_HUMAN,A336S,0.548,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000053|ELME000085|ELME000269,-
FGFR1_HUMAN,A336T,0.729,Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Altered Metal binding (Pr = 0.30 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000053,-
FGFR1_HUMAN,L342K,0.943,Altered Metal binding (Pr = 0.30 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.9e-04); Altered Ordered interface (Pr = 0.26 | P = 0.02); Gain of Disulfide linkage at C341 (Pr = 0.20 | P = 0.02); Altered Stability (Pr = 0.16 | P = 0.02), ELME000120|ELME000182|ELME000337|PS00005,-
FGFR1_HUMAN,L349I,0.120,-,-,-
FGFR1_HUMAN,H351N,0.662,Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of N-linked glycosylation at H351 (Pr = 0.12 | P = 8.3e-03), ELME000063|ELME000070|PS00001,-
FGFR1_HUMAN,W355L,0.802,Altered Ordered interface (Pr = 0.30 | P = 4.7e-03); Loss of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000063|ELME000064|ELME000085|ELME000220,-
FGFR1_HUMAN,L356R,0.969,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Strand (Pr = 0.28 | P = 7.5e-03); Altered Stability (Pr = 0.15 | P = 0.02), ELME000063|ELME000064|ELME000146|ELME000220|ELME000231|ELME000333,-
FGFR1_HUMAN,M369I,0.286,-,-,-
FGFR1_HUMAN,T370A,0.237,-,-,-
FGFR1_HUMAN,T370P,0.660,Altered Transmembrane protein (Pr = 0.22 | P = 2.7e-03), ELME000052|ELME000136|ELME000159,-
FGFR1_HUMAN,I377V,0.201,-,-,-
FGFR1_HUMAN,V394A,0.210,-,-,-
FGFR1_HUMAN,V396T,0.270,-,-,-
FGFR1_HUMAN,Y397C,0.315,-,-,-
FGFR1_HUMAN,M399T,0.358,-,-,-
FGFR1_HUMAN,G402S,0.100,-,-,-
FGFR1_HUMAN,D554E,0.420,-,-,-
FGFR1_HUMAN,S588T,0.101,-,-,-
FGFR1_HUMAN,H589R,0.177,-,-,-
FGFR1_HUMAN,N590A,0.135,-,-,-
FGFR1_HUMAN,N590S,0.073,-,-,-
FGFR1_HUMAN,K598R,0.301,-,-,-
FGFR1_HUMAN,G660D,0.938,Loss of Acetylation at K655 (Pr = 0.26 | P = 9.7e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000008|ELME000220|ELME000316|PS00006,-
FGFR1_HUMAN,T678S,0.670,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.23 | P = 2.6e-03); Altered Metal binding (Pr = 0.18 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q680 (Pr = 0.07 | P = 0.02), ELME000053|ELME000063|ELME000163|ELME000182,-
FGFR1_HUMAN,H679P,0.854,Altered Ordered interface (Pr = 0.31 | P = 0.02); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03); Altered Metal binding (Pr = 0.18 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q680 (Pr = 0.07 | P = 0.02), ELME000053|ELME000136|ELME000159|ELME000163|ELME000182|ELME000358,-
FGFR1_HUMAN,S723T,0.323,-,-,-
FGFR1_HUMAN,N727H,0.420,-,-,-
FGFR1_HUMAN,V740I,0.136,-,-,-
FGFR1_HUMAN,Q813P,0.571,Loss of Helix (Pr = 0.29 | P = 0.01), None,-
FGFR1_HUMAN,G817S,0.297,-,-,-
FGFR1_HUMAN,H253P,0.932,Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 3.5e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of B-factor (Pr = 0.25 | P = 0.03), ELME000135|ELME000136|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,R254Q,0.858,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000146|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,K656E,0.842,Loss of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Acetylation at K655 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03), ELME000008|PS00004,-
FGFR1_HUMAN,A608D,0.930,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Allosteric site at Y613 (Pr = 0.24 | P = 0.01), None,-
FGFR1_HUMAN,M535K,0.914,Altered Coiled coil (Pr = 0.50 | P = 7.1e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Stability (Pr = 0.12 | P = 0.03), None,-
FGFR1_HUMAN,S96C,0.641,Loss of Intrinsic disorder (Pr = 0.36 | P = 0.04); Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 6.0e-04); Gain of Disulfide linkage at C101 (Pr = 0.25 | P = 7.2e-03); Loss of Proteolytic cleavage at D95 (Pr = 0.13 | P = 0.02), ELME000085|ELME000239,-
FGFR1_HUMAN,I239T,0.741,Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05); Altered Ordered interface (Pr = 0.33 | P = 8.8e-03); Altered Metal binding (Pr = 0.24 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Stability (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N240 (Pr = 0.14 | P = 7.9e-03); Gain of Sulfation at Y236 (Pr = 0.02 | P = 0.03), ELME000053|ELME000070|ELME000120,-
FGFR1_HUMAN,P28L,0.557,Loss of Intrinsic disorder (Pr = 0.37 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.07 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 5.2e-03), ELME000005|ELME000064|ELME000155|ELME000220|PS00006,-
FGFR1_HUMAN,R756H,0.626,Altered Metal binding (Pr = 0.44 | P = 6.6e-03), None,-
FGFR1_HUMAN,N264H,0.888,Loss of Relative solvent accessibility (Pr = 0.34 | P = 3.5e-03); Altered Metal binding (Pr = 0.31 | P = 4.5e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 3.8e-04); Loss of N-linked glycosylation at N264 (Pr = 0.21 | P = 2.5e-03); Altered Stability (Pr = 0.16 | P = 0.02), ELME000052|ELME000070|PS00001|PS00008,-
FGFR1_HUMAN,T340A,0.829,Altered Metal binding (Pr = 0.29 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000120|ELME000182,-
FGFR1_HUMAN,P366L,0.595,Altered Transmembrane protein (Pr = 0.28 | P = 4.8e-04); Altered Coiled coil (Pr = 0.08 | P = 0.04), None,-
FGFR1_HUMAN,D224E,0.870,Altered Metal binding (Pr = 0.28 | P = 6.7e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Altered Ordered interface (Pr = 0.23 | P = 0.05); Loss of N-linked glycosylation at N227 (Pr = 0.16 | P = 5.6e-03), PS00005,-
FGFR1_HUMAN,R627S,0.964,Altered DNA binding (Pr = 0.37 | P = 7.2e-04); Loss of Allosteric site at R627 (Pr = 0.30 | P = 4.1e-03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 3.6e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Catalytic site at R627 (Pr = 0.13 | P = 0.03), ELME000146|ELME000336|PS00109,-
FGFR1_HUMAN,H621R,0.917,Gain of Allosteric site at H621 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.17 | P = 9.3e-03), ELME000012|ELME000102|ELME000108|PS00109,-
FGFR1_HUMAN,P663S,0.885,Gain of Strand (Pr = 0.27 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000062|ELME000337|PS00005,-
FGFR1_HUMAN,P252R,0.900,Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of ADP-ribosylation at P252 (Pr = 0.23 | P = 0.01), ELME000012|ELME000136|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,K618N,0.890,Loss of Allosteric site at Y613 (Pr = 0.21 | P = 0.04), PS00005,-
FGFR1_HUMAN,P169L,0.795,Loss of Intrinsic disorder (Pr = 0.49 | P = 7.4e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Loss of Acetylation at K172 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
FGFR1_HUMAN,Y339C,0.952,Altered Metal binding (Pr = 0.38 | P = 9.4e-03); Altered Transmembrane protein (Pr = 0.37 | P = 1.9e-05); Altered Ordered interface (Pr = 0.36 | P = 2.1e-03); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02), ELME000120|ELME000182,-
FGFR1_HUMAN,G270A,0.867,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Altered Metal binding (Pr = 0.18 | P = 0.01), ELME000052|ELME000064|ELME000239,-
FGFR1_HUMAN,R744T,0.915,Gain of Loop (Pr = 0.30 | P = 5.1e-03), ELME000053|ELME000062|ELME000136|ELME000159|ELME000202|PS00005,-
FGFR1_HUMAN,T695I,0.906,Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|ELME000235|ELME000335,-
FGFR1_HUMAN,L712P,0.927,Altered Stability (Pr = 0.43 | P = 2.6e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Gain of Acetylation at K711 (Pr = 0.20 | P = 0.04), ELME000045|ELME000146|ELME000149,-
FGFR1_HUMAN,C736Y,0.959,Altered Metal binding (Pr = 0.43 | P = 5.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of Allosteric site at R734 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Loss of Disulfide linkage at C736 (Pr = 0.11 | P = 0.04); Gain of Sulfation at C736 (Pr = 0.03 | P = 0.02); Loss of N-terminal acetylation at M732 (Pr = 0.02 | P = 8.0e-03), None,-
FGFR1_HUMAN,W4L,0.789,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.23 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000045|ELME000137|PS00005,-
FGFR1_HUMAN,K5E,0.513,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Signal peptide (Pr = 0.12 | P = 1.6e-03); Gain of N-terminal acetylation at M1 (Pr = 0.02 | P = 5.1e-03), ELME000106|ELME000137|ELME000146|PS00005,-
